Patent · US Active

Predicting response to a HER inhibitor

US7981418B2 · kind B2 · utility

39Cited by

114References

64Claims

0Family size

Assignees

Genentech, Inc. · US
Hoffmann-La Roche Inc. · US

Inventors

Lukas C. Amler · Foster City, US
Merrill Birkner · San Francisco, US
Chin-Yu Lin · Hsinchu, TW
Joachim Moecks · Mannheim, DE
Andreas Strauss · Forchheim, DE

Key dates

Filing date	Mar 1, 2008
Grant date	Jul 19, 2011
Priority date	—
Expiry date	Apr 2, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.